Skip to main content
24/05/2023

Vall d'Hebron hosts a collaborative session on the design of clinical trials in non-alcoholic fatty liver disease

Dr. Joan Genescà i Dr. Jose Luís Calleja

Dr. Joan Genescà i Dr. Jose Luís Calleja

24/05/2023

The aim of this session was to highlight the needs and perspectives from the point of view of different areas involved in clinical trials: research, regulatory bodies and the pharmaceutical industry.

Vall d'Hebron hosted last April 28th the first edition of the workshop on clinical trials in patients with non-alcoholic steatohepatitis (NASH) with compensated cirrhosis, organized by Dr. Joan Genescà, head of the Hepatology Department and clinical director at the Digestive Diseases area at Vall d'Hebron University Hospital, head of the Liver Diseases research group at Vall d'Hebron Research Institute (VHIR) and head of the Advanced Chronic Liver Disease research group at CIBERehd (ISCIII), and Juan Manuel Pericàs, member of the Liver Diseases research group and of the aforementioned CIBERehd group.

The aim of this session was to highlight the needs and perspectives of the different stakeholders involved in a clinical trial: research, regulatory bodies and the pharmaceutical industry. During the day, the regulatory environment and restrictions imposed by regulatory agencies, patient profiling and screening, and possible alternatives for clinical trial design were discussed.

An exceptional aspect of this workshop was to have the participation of national and international experts from the different fields involved in this type of trials from the academic world and the pharmaceutical industry, which resulted in very productive and comprehensive discussions. "The value of this workshop is to bring together experts from different specialties (portal hypertension and cirrhosis, NASH, pharmaceutical industry and regulators) in the same space, which are essential elements when designing a clinical trial", explained Dr. Joan Genescà during the opening of the event.

This first event served to initiate a debate on the challenges faced by researchers in conducting these trials, which we hope can potentially contribute to new discussions and initiatives to advance the field.
 

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Joan Genescà Ferrer

Joan Genescà Ferrer

Head of group
Liver Diseases
Read more
Lluís Viladomiu Catà

Lluís Viladomiu Catà

Liver Diseases
Read more
Ester Palacio Gutierrez

Ester Palacio Gutierrez

Research technician
Liver Diseases
Read more
Montserrat Gomez Perez

Montserrat Gomez Perez

Liver Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.